GCP
VIR icon

GSA Capital Partners’s Vir Biotechnology VIR Stock Holding History

GSA Capital Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$685K Buy
76,416
+51,475
+206% +$410K 0.04% 723
2025
Q4 		$150K Buy
24,941
+10,195
+69% +$60.7K 0.01% 1477
2025
Q3 		$84K Sell
14,746
-53,062
-78% -$271K 0.01% 1540
2025
Q2 		$342K Buy
67,808
+49,409
+269% +$265K 0.02% 1178
2025
Q1 		$119K Buy
+18,399
New +$164K 0.01% 1476
2023
Q4 		– Sell
-117,131
Closed -$1.1M – 1963
2023
Q3 		$1.1M Buy
+117,131
New +$1.67M 0.09% 347
2022
Q1 		– Sell
-13,925
Closed -$583K – 1865
2021
Q4 		$583K Sell
13,925
-14,608
-51% -$572K 0.07% 507
2021
Q3 		$1.24M Buy
28,533
+23,032
+419% +$997K 0.13% 204
2021
Q2 		$260K Buy
+5,501
New +$250K 0.03% 1033

Other funds holding VIR

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.66B AUM 340.85% 1-Year Est. Return